Background: The study explored the effect of platelet-rich fibrin/biphasic calcium
Periodontitis is a complex, multifactorial disease characterized by a loss of connective tissue attachment and dental bone support with the destruction of periodontal tissues. 1 Albandar and Rams 2 have reported that the people of Asian ethnicity had the third highest prevalence of periodontitis. It is reported that > 50% of the Indian population are affected with periodontal disease. 3 High prevalence of periodontal diseases is seen in India because of the vast population and lack of paradental infrastructures in rural and primary health centers. 3 Existing treatment of periodontitis is to eliminate infection and regenerate the lost supporting periodontal tissues and bone; and the treatment includes administration of antibiotics, mechanical debridement, root biomodifications and regenerative procedures such as bone grafting 4, 5 Concerns pertaining to the risk of second surgical site 6 have prompted the development of synthetic materials as an alternative. Some of the ideal, commercially available synthetic bone grafts are coralline-derived hydroxyapatite (HA), bioglass, calcium sulphate, synthetic HA, HA/calcium carbonate, -tricalcium phosphate and biphasic calcium phosphate. 7 Bioceramics have been commonly used as synthetic bone graft material for periodontal regeneration. 8 Biphasic calcium phosphate (BCP) is a type of bioceramic which is widely used as bone substitutes and are available in a variety of different forms, such as, powders, granules, and macroporous blocks for filling bone defects. 9 Several in-vivo studies have reported the use of BCP as bone substitute to fill defects generated in rabbit, 10 dog, 11 mouse, 12 and rat. 13 Recent reports have documented the use of BCP in human patients in maxillofacial surgery. 14 Platelet-rich fibrin (PRF) is categorized as a second generation platelet concentrate as it is prepared as a natural concentrate without any anticoagulants. 15 Presently, PRF is widely used in treatment of periodontal intrabony defects, treatment of furcation, sinus lift procedures, and tissue engineering. 16, 17 Studies reported in the past have implicated PRF in a variety of cellular functions such as cell attachment, proliferation and differentiation of osteoblast 18, 19 upregulation of osteoprotegerin, and alkaline phosphatase expression, 20 signal transduction. 18, 20 Programmed cell death through apoptosis plays a major regulatory role in homeostasis by maintaining a balance between cell proliferation and cell death. 21 Apoptosis plays a vital role in the regulation of osteoclasts-mediated bone resorption. Therefore, a new treatment approach for periodontitis could be achieved by attenuation of osteoclasts formation and regulation of osteoclasts apoptosis. It has been demonstrated that blood clotted around biphasic calcium phosphate (BCP) microparticles could be used for bone defect filling. Such a perceptive could be crucial for developing PRF/BCP as agents for the periodontal regeneration. The present study is an effort to investigate the hypothesis that PRF/BCP may play a role in inhibiting osteoclasts differentiation and in bone loss. More specifically, it addresses the question of its role in apoptosis of osteoclasts. Therefore, we focused on the population of monocytes-enriched fraction from peripheral blood of patients with chronic periodontitis and corresponding healthy individuals. Using these monocyte-derived osteoclasts progenitors, we aimed in the present report at the elucidation of proteins and transcriptional profiles of genes related to apoptosis and osteoclast differentiation in CD14 + cells.
MATERIALS AND METHODS

Drugs and reagents
Bone BCP * was composed of 60% hydroxyapatite (HA) and 40% beta-tricalcium phosphate ( -TCP) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), † dimethyl sulphoxide (DMSO), † recombinant human soluble RANKL (sRANKL) and recombinant human soluble M-CSF (sM-CSF), ‡ antibodies against Bax § , Bcl-2 § , Bcl-xL § , NF-B § , caspase 3 § and caspase 9 § horseradish peroxidase § and caspase-3 activity assay kit. ¶ Study protocol was approved by the institutional ethical review board (MU-107-IEC-2014) and the ClinicalTrials.gov protocol -ID (NCT032227367). The nature and purpose of the study was explained to all the participants, and written informed consent was obtained. * Sigma Graft, Fullerton, CA † Sigma-Aldrich, St. Louis, MO ‡ BioVision, Milpitas, CA § Santa Cruz, CA ¶ Sigma-Aldrich, St. Louis, MO
Study design
Inclusion and exclusion criteria
Participants having generalized severe periodontitis, according to the 1999 Classification of periodontal diseases and conditions, were included for the investigation. 22 Inclusion criteria for chronic periodontitis included presence of at least 20 teeth in the oral cavity, >30% of the sites with clinical attachment loss of ≥5 mm, non-smokers and no previous history of periodontal disease. Healthy individuals included the volunteers who were systemically and periodontally healthy. Individuals with systemic disease, patients under antibiotics or anti-inflammatory drugs within the previous 3 months, and pregnant and lactating women were excluded from the present study.
Demographic variables
The healthy individuals (control group) were matched and paired with chronic periodontitis patients (test group) for age, height, weight, and BMI (body mass index), because these parameters are established as risk determinants for periodontitis. A brief case history was taken, which included patient's chief complaint and medical and dental history by a written questionnaire and by an interview.
Screening of periodontitis
In both groups, the quantity of microbial dental plaque was determined using the Silness and Löe plaque index (PI), 23 and gingival status was assessed using the Löe gingival index (GI). 24 Customized acrylic stents with grooves were used for measurement of all clinical parameters using a periodontal probe. PI and GI were evaluated at six sites per tooth. Clinical parameters were recorded for the entire dentition.
Isolation of monocytes from whole blood
Seven milliliters of peripheral blood was used to separate mononuclear cells from the participants in both groups i.e, chronic periodontitis (test group) and healthy individuals (control group). Mononuclear cells were prepared from diluted peripheral blood (1:2 in phosphate buffered saline [PBS]), which was layered over Ficoll-Hypaque solution, centrifuged at 1,700 rpm, for 30 minutes at room temperature, washed and resuspended in Dulbecco's modified Eagle's medium (DMEM), * containing 10% fetal bovine serum (FBS). † Subsequently, cells were counted in a hematocytometer using tryphan blue. * Sigma-Aldrich, St. Louis, MO † Gibco, Grand Island, New York
Quantification of osteoclast precursors
Flow cytometry was used to determine the percentage of CD14 + cells in peripheral blood mononuclear (PBMCs) samples from both the groups i.e, chronic periodontitis (test group) and healthy individuals (control group). After cells were counted, 1 × 10 6 PBMCs were centrifuged and incubated in PBS with a dilution 1:10 of FITC-conjugated anti-human CD14 antibody for 30 minutes. Then, cells were washed, suspended in PBS, and analyzed by flow cytometry. ‡
MTT assay
PBMCs were seeded in 96-well plates at a density of 5 × 10 3 cells/well in 200-L DMEM containing 10% FBS and incubated overnight. Non-adherent cells were removed by gentle washing after 24 hours. Then cells were replaced with serum free medium with varying concentrations of biphasic calcium phosphate (20 to 100 g/mL). A negative control containing serum-free medium with DMSO was also evaluated. After 24 hours of treatment, the plates were incubated with 20-L 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/mL) for 3 hours at 37 • C. The formazan was dissolved in 150-L/well DMSO and the absorbance was detected at 590 nm using a microplate reader. § Cell viability was expressed as a percentage of untreated cells, which served as the negative control group and was designated as 100%; the results were expressed as a percentage of the negative control.
Preparation of PRF and BCP (see Appendix 1 in online Journal of Periodontology) PRF preparation method was followed by protocol proposed by Choukroun et al. 25 Human primary osteoclasts generation and differentiation (see Appendix 2) Western blot analysis (see Appendix 3) RNA Extraction and cDNA Synthesis (see Appendix 4)
Statistical analysis
All data are expressed as mean ± SD. A statistical software package ¶ was used and changes were considered significant at the P < 0.05 level. Analysis of variance (ANOVA) was used for assessment of statistical significance among groups for periodontal and clinical parameters. ‡ BD Biosciences, San Jose, CA § Bio-Rad Laboratories, Hercules, CA ¶ SPSS, v.10.0, Chicago, IL.
RESULTS
Demographic distribution of patients and clinical parameters
The study population consisted of 55 participants from a suburban area; five refused to participate in the study, and 25 healthy individuals (mean age, 27.45 ± 2.82 years) and 25 chronic periodontitis patients (mean age, 35.05 ± 4.32 years) were selected for the study. The mean age, height, weight and BMI, and periodontal status in both the groups were compared and it was found that there were significant differences between the groups with respect to age and periodontal parameters such as percentage of BOP (bleeding on probing), PI (plaque index), GI (gingival index) and CAL (clinical attachment level) (see supplementary Table 2 in online Journal of Periodontology).
Circulating osteoclast precursors
Using flow cytometry and an antihuman CD14 antibody, we demonstrated that CP patients had relatively more CD14 + cells in their PBMC preparations (19.57 ± 0.545) than healthy individuals (15.73 ± 0.375, P < 0.01) (see supplementary Figure 2A in online Journal of Periodontology).
MTT assay
Supplementary Figure 2B in the online Journal of Periodontology showed the percentage of viable cells obtained in the MTT assay with varying concentrations of BCP (20 to 120 g/mL) on osteoclast precursor cells. Based on the cell viability test, BCP at 60 g/mL does not significantly affect the viability of the cells. Therefore, all subsequent in-vitro studies with the osteoclast precursor cells were preformed with BCP at 60 g/mL.
PRF/BCP inhibits osteoclast differentiation in RANKL-cultured PBMCs
Tartrate-resistant acid phosphatase (TRAP) is a well-known enzyme that is widely accepted to be a staining marker of osteoclasts, and it can be significantly elevated by RANKL stimulation. 26 TRAP-positive multinucleated osteoclasts were quantified microscopically. RANKL treatment in the test group induced osteoclast formation from preosteoclast cells and dramatically enhanced TRAP positivity ( Figures 1A  and 1B) . Treatment with BCP (P < 0.001), PRF (P < 0.001) and PRF/BCP combination (P < 0.001) reduced the number of multinucleated TRAP-positive cells than CP. 
DNA fragmentation assay
To delineate the mechanism of cell death mediated by PRF/BCP, we performed DNA fragmentation assay, which is characteristic for apoptosis. The cells were treated with PRF, BCP alone, and PRF/BCP combination for 24 hours, and DNA was then isolated and analyzed by agarose gel electrophoresis. Following agarose gel electrophoresis, a typical ladder pattern of internucleosomal DNA fragmentation was observed. These data suggest that PRF/BCP is a potent inducer of apoptosis in osteoclast cells (Figure 2 ).
PRF/BCP altered anti-apoptotic and pro-apoptotic protein and mRNA expression in osteoclast cells
Various proteins are implicated in the regulation of apoptosis. 27 It has been demonstrated that the Bcl-2 gene product confers resistance to apoptosis induced by a number of stimuli, while its homolog, Bax, promotes apoptosis. 27 To investigate the mechanism through which PRF/BCP induces apoptosis, here, we tested the expressions of Bax, Bcl-xL, Bcl-2, and NF-B in osteoclast cells using Western blot analysis. The results showed that the level of pro-apoptotic protein Bax in BCP (1.42-fold, P < 0.01), PRF (1.90-fold, P < 0.001), and a combination of PRF/BCP (2.1-fold, P < 0.001) were higher than CP. In contrast, the levels of anti-apoptotic proteins Bcl-2, BclxL in BCP (0.84-fold, P < 0.05; 0.69-fold, P < 0.01), PRF (0.41-fold, P < 0.001; 0.32-fold, P < 0.001), and PRF/BCP (0.28-fold, P < 0.001; 0.29-fold, P < 0.001) combination were lower than CP ( Figures 3A and 3B) . Reverse transcriptionpolymerase chain reaction (RT-PCR) analysis showed that the mRNA level of Bax was increased in BCP (1.22-fold, P < 0.01), PRF (1.26-fold, P < 0.001), and a PRF/BCP combination (1.50-fold, P < 0.001), as compared with CP. The gene expression of anti-apoptotic proteins Bcl-2 and Bcl-xL was found to be decreased in BCP (0.76-fold, P < 0.01; 0.70-fold, P < 0.01), PRF (0.50-fold, P < 0.001; 0.44-fold, P < 0.001), and PRF/BCP combination (0.15-fold, P < 0.001; 0.38-fold, P < 0.001) when compared with CP ( Figures 4A and 4B ).
PRF/BCP suppresses RANKL-induced NF-B activation
The blockage of apoptosis and cell proliferation is closely associated with activation of NF-B. 28 So we examined the role of PRF/BCP in the inhibition of activated NF-B by Western blot and RT-PCR analysis. The protein level of NF B in BCP (0.89-fold; P < 0.05), PRF (0.30-fold, P < 0.001), and PRF/BCP combination (0.28-fold, P < 0.001) was dramatically diminished when compared with CP ( Figures 3A and  3B ). In parallel, the gene expression of NF-B was markedly inhibited in BCP (0.83-fold; P < 0.05), PRF (0.67-fold, P < 0.001), and PRF/BCP combination (0.30-fold, P < 0.001) when compared with CP ( Figures 4A and 4B ).
PRF/BCP-induced activation of caspase-3 and caspase-9 in mature osteoclasts
Caspase-3 and caspase-9 are the most prevalent caspases and is responsible for a majority of apoptotic effects. Using Western blot analysis, we assessed the protein levels of caspase-3 and caspase-9. Our results showed that the levels of caspase-3 and caspase-9 were elevated in BCP (1.20-fold, P < 0.001; 1.50-fold, P < 0.001), PRF (1.60-fold, P < 0.001; 1.96-fold, P < 0.001), and PRF/BCP combination (2.2-fold, P < 0.001; 2.6-fold, P < 0.001), respectively ( Figures 3A and  3B) . Similarly, as shown in Figures 4A and 4B , mRNA levels of caspase-3 and caspase-9 showed significant (P < 0.001) increase in BCP (1.25-fold, P < 0.01; 1.30-fold, P < 0.01), PRF (1.47-fold, P < 0.001; 2.10-fold, P < 0.001), and PRF/BCP combination (1.92-fold, P < 0.001; 2.29-fold, P < 0.001) when compared with CP. In addition, the activity of caspase-3 in osteoclasts was also measured. The cells treated with PRF/BCP showed a significantly (P < 0.001) higher activity of caspase-3 when compared with CP ( Figure 5 ). These results further indicate that PRF/BCP induces caspase-3 activation, which is associated with the reduced survival and increased osteoclasts apoptosis.
DISCUSSION
This is the first study to assess the impact of PRF/BCP composite on human monocytes lineage cells derived from patients with chronic periodontitis (CP), and more specifically on their differentiation into osteoclasts and on apoptosis. This study indicates that PRF/BCP composite promotes the apoptosis of osteoclasts by mitochondrial apoptosis pathway in vitro. Representative RT-PCR gel image. B) Results were expressed as the mean ± SEM. *Significant difference was seen between CP and BCP (P < 0.05), † CP and PRF (P < 0.01), ‡ CP and PRF/BCP combination (P < 0.001)
F I G U R E 5 Effects of PRF/BCP on the activity of caspase-3 in
OCs. Results were expressed as the mean ± SEM. *Significant difference was seen in CP and BCP (P < 0.05), † CP and PRF (P < 0.01), ‡ CP and PRF/BCP combination (P < 0.001) and 1B). There was a relative increase in the number of TRAPpositive multinucleated osteoclasts in untreated cells (CP) than BCP (P < 0.001), PRF (P < 0.001), PRF+BCP combination (P < 0.001) in vitro. Moreover, OCs in the CP group were larger than other groups. It has been established that larger OCs are more active at bone resorption sites than smaller cells accounting for excessive bone loss. 29 We studied the percentage of CD14+ cells, precursors of osteoclasts in healthy individuals and test group. The increased number of OCs found in the test group could be a consequence of several different factors (see supplementary Figure 2A in online Journal of Periodontology). Osteoclast precursors are marrow-derived cells which circulate in the CD14 + fraction of PBMCs. The test group presented with the higher percentage of CD14 + OC precursors than the healthy group suggesting that this contributes to the large number of OC found in the test group. 30, 31 These results suggest that most of the CD14 + cells produced in chronic periodontitis represent osteoclast precursors. This finding is similar to previous in-vitro studies, which have shown that the propensity of the osteoclast precursor cells may decrease to recruit and stimulate the formation of osteoclasts in vitro. 32 In addition, PRF/BCP may oppose the differentiating effects of M-CSF and RANKL and reduces the formation of osteoclasts by limiting the differentiation of precursors into mature multinucleated osteoclasts. Bölükbaşı et al. 33 also demonstrated the use of platelet-rich fibrin in combination with biphasic calcium phosphate in the treatment of bone defects.
The intensity of either local or generalized bone resorption by OCs depends on the number of OCs formed, on the intrinsic activity of these cells as well as on their survival. 34 Thus, factors inducing osteoclastogenesis or apoptosis may be important in the pathophysiology of bone destruction. In recent years, apoptosis of osteoclasts have been considered as an important therapeutic target in the treatment for bone resorption. 35 Recent advances in elucidating the mechanism of OCs differentiation revealed that nuclear factor-B (NF-B), is essential for osteoclastogenesis and regulation of OCs apoptosis. 36 Since the transcription factor NF-B has been reported to be important for the expression of several apoptotic-related genes, we verified whether PRF/BCP were able to inhibit the biological activity of this factor. A high level of inhibition of NF-B was found following treatment with BCP, PRF alone, and PRF/BCP combination demonstrating that NF-B dependent functions are impaired ( Figure 3A and Figure 4A ). On the basis of this experimental evidence, we propose that, the pro-apoptotic action of PRF/BCP combination on osteoclasts could be mediated, in part, by interfering with NF-B activity.
The osteoclasts undergo spontaneous apoptosis through the activation of the death receptor pathway or mitochondrial apoptosis pathway. 37 The intrinsic mitochondrial apoptotic pathway is characterized by the release of cytochrome c from permeabilized mitochondria into cytosol and activation of caspases. This release is mediated by activated Bax and deregulation of Bcl2. These activated proteins trigger mitochondrial outer membrane permeabilization (MOMP), which thereby releases cytochrome c and activates caspase 9, which in turn activates caspase-3 and -7 which leads to apoptotic cell death. 37 Research into the molecular mechanisms of the apoptotic stimulus has uncovered the Bcl-2 protein family that is thought to function as apoptosis regulators. 38 We studied the molecular basis of induction of apoptosis in BCP, PRF alone, and PRF/BCP treated cells. PRF/BCP promotes the expression of pro-apoptotic protein Bax which could be a sign of induction of apoptosis and inhibits the expression of anti-apoptotic Bcl-2 and Bcl-xL, leading to an increased ratio of Bax/Bcl-2. In addition, mRNA transcripts of Bax ( Figure 4A ) were increased and Bcl-2 and Bcl-xL were decreased ( Figure 4A ). This has reinforced the mitochondrial apoptotic scenario as the increase in Bax:Bcl-2 ratio act as upstream modulators of this cascade. Bcl-2 family members are capable of forming homo-and heterodimers with one another suggesting that the overall ratio of proto anti-apoptotic regulators may determine whether a cell is condemned to die of apoptosis or not. 39 Kasprzak et al. 40 demonstrated the greater expression of apoptotic protein Bcl-2 in gingival tissues of patients with chronic periodontitis. Lundmark et al. 41 reported the expression of apoptosisrelated genes in gingival tissues, and Liu et al. 42 demonstrated that apoptotic proteins were upregulated in peripheral blood monocytes of patients with chronic periodontitis by DNA microarray studies.
After an apoptotic signal stimulates Bax gene expression, and it translocates to the mitochondria, apoptotic initiators caspase-8 and -9 are activated, thus triggering downstream effectors, including caspase-3. 43 Caspase-3 is considered as a critical executioner of apoptotic signaling pathway since it can be activated by several other active caspases, and also it has catalytic specificity for an appropriate number of important cellular substrates. Caspase-3 acts as the definitive enforcer of cellular apoptotic death, and the activation of caspase-3 represents the irreversible phase of apoptosis. 44 A previous study reported that the activation of caspase-3 was required for osteoclast differentiation. 44 In the present study, BCP, PRF and PRF/BCP combination promoted the cell death signal by involving caspase-3 and -9. Enhanced caspase-3 and -9 expressions were found by Western blot suggesting that the pro-apoptotic function of caspase-3 and -9 might play an important role in PRF/BCP-induced apoptosis ( Figure 3A) . The detection of the increased Caspase 3 activity is an evidence of apoptotic mechanisms are in progress ( Figure 5) . A previous study has revealed that apoptotic proteins and caspase-3/7 activities increased in periodontal tissues. 45 Therefore, it is assumed that BCP, PRF alone, and PRF/BCP increased the permeability of the mitochondrial membrane and promoted the release of cytochrome C and other pro-apoptotic factors into the cytoplasm, thereby initiating the caspase-dependent apoptosis of osteoclasts. Also, we observed genomic DNA fragmentation, in BCP, PRF, and PRF/BCP combination which is the late biomarker of apoptosis ( Figure 2 ). This could be due to the chromatin condensation and inter nucleosomal cleavage of DNA. However, CP showed the decreased fragmented laddering pattern of DNA. In summary, this study suggests that PRF/BCP promotes osteoclasts apoptosis and inhibits osteoclasts generation in vitro.
The improved results obtained in PRF/BCP combination group suggest a greater effect of PRF when used in association with BCP than when used alone. The combination of PRF and BCP is likely to create a composite with both osteoconductive and osteoinductive properties.
The main advantage of BCP (HA/ -TCP) is that its chemical composition is similar to that of apatite in biological bone. 46, 47 The release of calcium ions favor the formation of an apatite layer, which is necessary for the osteoconductivity and osteoinductivity demonstrated in BCP ceramics. 48 In osteoconduction, the biomaterial supports the growth of mature osteoblasts, while in osteoinduction, it stimulates the differentiation of immature cells towards the osteoblastic lineage and as a result, osteogenesis will be stimulated. The combination of PRF with BCP is opening the door to novel therapeutic alternatives and improving pre-existing ones, increasing the usefulness of bone substitute materials.
The most obvious limitation of the study is its study design. The treatment with PRF/BCP was limited to patients with chronic periodontitis. Firm conclusions can be drawn if the control group is included and treated with PRF, BCP, or PRF/BCP. Also, the investigation was confined to only one time point, 24 hours. The replication of the study at different time points would enable better inference of the study. Studies with much larger sample size may ensure appropriate conclusion to the research.
CONCLUSIONS
All these data indicate that apoptotic mechanisms seem to play an important role in the pathogenesis of periodontitis. PRF/BCP inhibits osteoclasts attachment to bone matrix and induces apoptotic signaling cascade. Therefore, PRF/BCP composite targeting apoptosis may display favorable effects in combating alveolar bone resorption in chronic periodontitis. Based on these findings, we propose that a major role of PRF/BCP is to limit osteoclastogenesis through promotion of proteolytic cascade of apoptosis. Therefore, it might be relevant to use PRF/BCP composite to fill bone defects to improve local bone regeneration.
